President and CEO of InterVivo Solutions, a specialized CRO focused on optimizing translational services to facilitate the development of CNS drugs.
More than 35 refereed publications and several invited presentations, which focus on natural aged canine models of human disease.
Has co-founded, held executive positions and consulted for Life Science companies including CanCog Technologies, Vivocore, Karyopharm Therapeutics, NPM Pharma and Ketogen.
Has conducted extensive research examining psychoactive drugs.
Malik Slassi
Chief Scientific Advisor
Founder, President & Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium Therapeutics in January 2016.
30 + years of experience in successful identification & development of small molecule drug candidates across multiple therapeutic areas, including CNS.
Former Senior Vice President of Discovery Research at Trillium Therapeutics and Vice President of Medicinal Chemistry, Manufacturing & Development at Cascade Therapeutics, and earlier Dr. Slassi held management & scientific positions at Allelix Biopharmaceuticals, Bio-Mega/Boehringer-Ingelheim Research and NPS Pharmaceuticals.
Involved in multinational R&D collaborations with Hoechst AG (Sanofi-Aventis), AstraZeneca, Johnson & Johnson, Forest Laboratories, GlaxoSmithKline, Memory and Shire Pharmaceuticals.
Over 24 drug candidates advanced into late-stage preclinical, clinical development & market; co-authored over 65 research papers and review articles, and he is an inventor of over 130 issued patents & patent applications.
Holds a Ph.D. in chemistry from the University of Claude Bernard, Lyon, France and completed his postdoctoral work in the Chemistry Department at the University of Montreal, Canada.
Michael Rogawski
Scientific Advisor
Professor of Neurology and Pharmacology at the University of California, Davis School of Medicine.
Serves as lead of the University of California Drug Discovery Consortium.
Formerly chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke.
Member of board of directors of the American Epilepsy Society.
Authored more than 275 research papers, reviews, and book chapters, and edited five books.
Received M.D. and Ph.D. (Pharmacology) from Yale and trained in neurology at Johns Hopkins.
Guy Higgins
Scientific Advisor
20+ years leading International CNS Research and Development experience with major BioPharma organisations such as Glaxo-Wellcome, Hoffmann-La Roche, Schering Plough and NPS Pharmaceuticals.
Supported the identification and progression of novel chemical entities from early discovery through to clinical development (> 10 entering IND phase, 3 to market).
Significant background in serotonin research both in terms of contributions to drug discovery programs and applied research.
Co-authored over 150 research papers and review articles covering aspects of CNS pharmacology, drug discovery and behavioural neuroscience. Over 70 publications in serotonin based research.
Received PhD in 1990 and currently holds the position of Adjunct Professor in the Pharmacology department at the University of Toronto.
